Verona Pharma plc
VRNA
Kedudukan dalam Saham
#2228
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Harga Saham
$106.91
Disegerakkan terakhir: 2025-10-07
Modal Pasaran
$9.09B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Verona Pharma plc (VRNA)
Kategori
Healthcare
Bilangan saham terbitan bagi Verona Pharma plc (VRNA)
Bilangan saham terbitan setakat June 2025: 85.64M
Menurut laporan kewangan terkini dan harga saham Verona Pharma plc, bilangan saham terbitan semasa ialah 85.64M. Pada akhir December 2023, syarikat mempunyai 75.51M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Verona Pharma plc (VRNA) dari 2005 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 85.64M | 6.67% |
| 2024 | 80.29M | 6.32% |
| 2023 | 75.51M | 14.31% |
| 2022 | 66.06M | 11.68% |
| 2021 | 59.15M | 79.97% |
| 2020 | 32.87M | 149.64% |
| 2019 | 13.17M | 0.21% |
| 2018 | 13.14M | 19.79% |
| 2017 | 10.97M | 161.94% |
| 2016 | 4.19M | 65.85% |
| 2015 | 2.52M | 16.52% |
| 2014 | 2.17M | 154.03% |
| 2013 | 853.00K | 11.28% |
| 2012 | 766.55K | -0.19% |
| 2011 | 768.03K | 0.00% |
| 2010 | 768.03K | 0.00% |
| 2009 | 768.03K | 0.00% |
| 2008 | 768.03K | 0.00% |
| 2007 | 768.03K | 0.00% |
| 2006 | 768.03K | 0.00% |
| 2005 | 768.03K | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 196.46% |
US
|
|
| 396.00M | 362.37% |
US
|
|
| 478.91M | 459.18% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -27.39% |
NL
|
